DashboardAll companies
Run this on your own research
Healthcare · Biotechnology

D&D Pharmatech Inc.

347850KRX₩40,850−₩850 (−2.04%)Market closed

Price Chart

Daily

Key facts

Market Cap
₩1.88T
P/E
−74.7x
P/B
22.13x
ROE
−31.5%

D&D Pharmatech Inc.

Healthcare · Biotechnology · FY 2025

D&D Pharmatech Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapeutic solutions. The company primarily focuses on advancing treatments for central nervous system disorders, metabolic diseases, and fibrotic diseases, with a robust pipeline of drug candidates in various stages of clinical trials. Utilizing cutting-edge scientific research and strategic partnerships, D&D Pharmatech aims to address unmet medical needs, enhancing the lives of patients while contributing to advancements in medical science. With operations that span drug discovery to clinical development, the company plays a significant role in the biotechnology sector, impacting both healthcare providers and patients. By leveraging proprietary technology platforms, D&D Pharmatech is positioned at the forefront of biopharmaceutical innovation, reinforcing its commitment to driving transformative medicine. Its contributions to the biotech industry are marked by a strong emphasis on research and development, exemplifying the dynamic nature of the sector and its potential to disrupt traditional treatment paradigms.

CEO
이슬기
Employees
21

Company Statistics

Valuation

P/E
−74.7x
P/B
22.13x
P/S
409.31x
EV/EBITDA
−59.2x
P/FCF
−83.0x

Margins

Gross
100.0%
EBITDA
−680.6%
Operating
−791.0%
Pre-Tax
−579.4%
Net
−558.0%

Returns

ROA
−24.6%
ROE
−31.5%
ROIC
−25.1%

Growth (CAGR)

Rev 3Yr
91.6%
Rev 5Yr
—
Op Inc 3Yr
—
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
₩32.88B
Net Debt
−₩14.32B
Debt/Equity
23.5%
Interest Cov
—

Profile

Revenue
₩4.30B
Shares Out
46.0M
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
D&D Pharmatech Inc. (347850) Stock Forecast 2026 ₩40,850 — Price, Financials & Analyst Targets | AlphaLenz